All In Biotech

NDA 206709 · Biocodex SA

Diacomit

Stiripentol · Oral

NovelPriority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Apr 15, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Aug 20, 2018

Approved uses

2

Original approval plus efficacy supplements

Registered trials

14

4 Phase 3, 2 recruiting

FAERS reports

2,283

1,959 serious, 121 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 27, 2026.

DIACOMIT is indicated for the treatment of seizures associated with Dravet syndrome (DS) in patients taking clobazam who are 6 months of age and older and weighing 7 kg or more. There are no clinical data to support the use of DIACOMIT as monotherapy in Dravet syndrome. DIACOMIT is indicated for the treatment of seizures associated with Dravet syndrome in patients taking clobazam who are 6 months of age and older and weighing 7 kg or more . There are no clinical data to support the use of DIACOMIT as monotherapy in Dravet syndrome. ( 1 )

Mechanism: The mechanism by which DIACOMIT exerts its anticonvulsant effect in humans is unknown. Possible mechanisms of action include direct effects mediated through the gamma-aminobutyric acid (GABA) A receptor and indirect effects involving inhibition of cytochrome P450 activity with resulting increase in blood levels of clobazam and its active metabolite.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • DIACOMIT · STIRIPENTOL 500MG · CAPSULE, ORAL · Prescription
  • DIACOMIT · STIRIPENTOL 250MG · CAPSULE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Stiripentol" as an intervention, any sponsor and status, largest first.

All 14 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • seizure928
  • off label use443
  • product use in unapproved indication351
  • drug ineffective306
  • decreased appetite265
  • somnolence246
  • product preparation issue201
  • product dose omission issue186
  • fatigue138
  • pyrexia113
  • weight decreased111
  • hospitalisation107

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20044
20051
20063
20074
20085
20091
20103
201112
20125
20137
20145
201521
201614
201742
201850
2019239
2020247
2021284
2022276
2023186
2024234
2025303
2026337

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Diacomit (Stiripentol)

2024 spending

$1.7M

Beneficiaries

32

296 claims

Per beneficiary

$54,459

$41.82 per unit

View as table
YearSpending
2020$0
2021$468,575
2022$854,407
2023$1,207,655
2024$1,742,694

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 49 on PubMed

Sponsor: Biocodex SA

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.